Delivery Hero increases provisions for riders' status in Italy
April 11 (Reuters) - Glovo's owner Delivery Hero (DHER.DE), opens new tab has increased provisions related to the legal status of its riders in Italy and said in a statement that the increased expenses are reflected in its adjusted earnings for the 2024 financial year.
The increase in provisions, that now amount to a total 253 million euros ($286.78 million), is meant to cover social security contributions, interest and fines that Italian authorities may claim for the period from 2016 until the end of 2024 for Glovo in the country.
here.
As it confirmed its 2025 outlook, the firm said the previously disclosed adjusted EBITDA of around 750 million euros for the 2024 financial year is now expected to come in at 693 million euros.
The German firm has been under scrutiny for the labour status of its riders and has been fined in Spain between 2022 and 2023 for not formally hiring them.
In December it said it would hire its freelance riders as full-time employees in Spain, warning of a 100 million euro hit to earnings.
($1 = 0.8822 euros)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
7 minutes ago
- Reuters
Reckitt eyes new options to advance Air Wick unit sale, sources say
LONDON, June 3 (Reuters) - Britain's Reckitt (RKT.L), opens new tab is considering new options to advance a sale of its Essential Home business, home to Air Wick fresheners and Cillit Bang cleaners, after bids came in below expectations, two people with knowledge of the process said. The company still plans to pursue a sale, the people said, who spoke on condition of anonymity because the talks are private. Private equity firm Advent remains in talks for the assets, one of the people and a third person said. Reckitt, which also makes Mucinex cold medication and Durex condoms, said in July it was looking to offload a portfolio of homecare brands by the end of 2025. The proposed sale comes at a challenging time for businesses with factories around the world as they navigate U.S. President Donald Trump's tariffs, which are roiling supply chains, boosting costs and dampening shopper sentiment. Reckitt could keep a stake in the business or structure a sale another way to bridge a gap in valuations, one of the people said, adding that some of the bids came in below its hopes of over 4 billion pounds ($5.4 billion). Reuters could not determine if other bidders remained in the process. Reckitt and Advent declined to comment. Bankers and CEOs have hit the brakes on mergers and acquisitions since Trump launched his trade war, with fewer deals getting signed than during the bleakest days of the COVID-19 pandemic and the 2008-2009 global financial crisis. Reckitt said in April that it was "continuing to progress" the sale of the Essential Home business but that market conditions might affect the time frame. Consumer staples companies are considered relatively resilient to economic downturns, but big brands like Reckitt, P&G (PG.N), opens new tab and Unilever (ULVR.L), opens new tab increasingly face competition from cheaper private label brands that gained popularity during the pandemic. Reckitt's Essential Home business has struggled for several quarters, with sales falling 7% in the first quarter of this year to 482 million pounds, about 13% of total revenue for the quarter. Reckitt has been undergoing a turnaround under CEO Kris Licht, who has sought to reassure shareholders concerned about the strength of the company's brands in North America and Europe, where consumer confidence has been dwindling. ($1 = 0.7397 pounds)
Reuters
18 minutes ago
- Reuters
India's HDB Financial gets market regulator nod for IPO
MUMBAI/BENGALURU, June 3 (Reuters) - India's markets regulator, the Securities and Exchange Board of India (SEBI), has approved the initial public offering (IPO) of HDB Financial Services, marking the HDFC group's first public float in seven years. According to a document published on the SEBI website on Tuesday, the regulator issued observations on the public listing, allowing the company to proceed with its IPO, a source with direct knowledge of the matter said. SEBI and HDFC Bank ( opens new tab did not immediately respond to a Reuters request for comment. In October, HDB Financial filed for an IPO of up to 125 billion rupees ($1.5 billion). HDFC Bank, which holds a 94.3% stake in the lender, will sell shares worth up to 100 billion rupees, while fresh shares worth up to 25 billion rupees will be issued. HDB Financial's listing follows new norms introduced by the country's central bank in 2022 that require large non-banking financial companies to be listed on stock exchanges by September 2025. For the quarter ended March 31, HDB Financial Services posted a profit of 5.3 billion rupees, while its net revenue came in at 26.2 billion rupees. The company's total loan book was 1.07 trillion rupees as of March-end. ($1 = 85.6540 Indian rupees)
Reuters
20 minutes ago
- Reuters
Sanofi to buy US biopharma group Blueprint for up to $9.5 billion
PARIS, June 2 (Reuters) - France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in rare immunology diseases, in the biggest deal struck by a European healthcare company so far this year, according to LSEG data. Blueprint (BPMC.O), opens new tab is a specialist in treatments for systemic mastocytosis, a rare blood disorder. Sign up here. The two companies said on Monday that Sanofi ( opens new tab would initially pay $129.00 per share in cash, or around $9.1 billion. Blueprint shares jumped 27% to $128.74 in premarket trade. Sanofi stock was down about 1%. Sanofi has ramped up research and development spending in recent years, prompting the company to abandon its long-term profit margin targets two years ago, as it seeks to build on the success of its blockbuster drug Dupixent for eczema and other conditions. However, it suffered a setback last week after an experimental drug for patients with a lung condition commonly called "smoker's lung" failed a late-stage trial. The Blueprint acquisition "represents a strategic step forward in our rare and immunology portfolios. It enhances our pipeline and accelerates our transformation into the world's leading immunology company," said Sanofi CEO Paul Hudson. The deal would add to Sanofi's portfolio the rare immunology disease drug Ayvakit, also known as Ayvakyt, approved in the U.S. and the EU, and a promising advanced and early-stage immunology pipeline. Ayvakit is the only approved medicine for advanced and indolent systemic mastocytosis, a rare blood disorder that occurs when the body makes abnormal mast cells - a type of white blood cell. It triggers a continuous allergic response. The acquisition would also bring elenestinib, a next-generation medicine for systemic mastocytosis, as well as BLU-808, a highly selective and potent oral wild-type KIT inhibitor that has the potential to treat a broad range of diseases in immunology. The deal makes "strategic and financial sense", said JP Morgan analysts in a note, noting that Blueprint expects Ayvakit to reach annual sales of around $2 billion by fiscal year 2030. "We see the transaction as a good fit for Sanofi at a sensible valuation, which investors should see as a positive with time," they added. It is the latest in a series of deals by Sanofi. Last month, it announced the $470 million purchase of Vigil Neuroscience (VIGL.O), opens new tab and in January 2024 it struck a $2.2 billion deal for U.S biotech firm Inhibrx. Hudson said the deal complemented Sanofi's recent acquisitions of other early-stage medicines and added that it still retained a sizable capacity for further deals. The company has said it plans to invest at least $20 billion in the United States through 2030 to boost manufacturing and research, joining other drugmakers in responding to President Donald Trump's drive to boost local manufacturing. Besides $129.00 per share in cash, Blueprint shareholders would also receive one non-tradeable contingent value right (CVR) per share, which would entitle the holder to receive two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. The total equity value of the transaction, including potential CVR payments, is $9.5 billion on a fully diluted basis. It is expected to close in the third quarter, pending regulatory and shareholder approvals.
